Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar;21(1):3-11.
doi: 10.3802/jgo.2010.21.1.3. Epub 2010 Mar 31.

Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies

Robert A Burger  1
Affiliations

Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies

Robert A Burger. J Gynecol Oncol. 2010 Mar.

Abstract

This article reviews the history and current status of vascular endothelial growth factor targeted therapy for the most common gynecologic malignancies - epithelial ovarian, endometrial and cervical cancers. The biologic rationale for targeting vascular endothelial growth factor (VEGF) for these disease sites is well-founded, and pre-clinical studies have supported the development of anti-VEGF agents. Their classification, known mechanisms of action, unique toxicities and clinical development are herein explored, the latter including issues related to study design, disease site and disease setting.

Keywords: Angiogenesis; Bevacizumab; Cervical neoplasms; Endometrial neoplasms; Ovarian neoplasms; Vascular endothelial growth factor.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

References

    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–249. - PubMed
    1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigel C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130. - PubMed
    1. Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res. 2003;9:5721–5728. - PubMed
    1. Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol. 2002;161:1917–1924. - PMC - PubMed
    1. Luo JC, Toyoda M, Shibuya M. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res. 1998;58:2594–2600. - PubMed